Neumora Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 124
- Market Cap
- $1.8B
- Website
- http://www.neumoratx.com
- Introduction
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Neumora Therapeutics' phase 3 KOASTAL-1 study of navacaprant in MDD fails to meet primary or key secondary endpoints
Neumora Therapeutics announced phase 3 KOASTAL-1 study results for navacaprant in treating major depressive disorder (MDD) did not meet primary or key secondary endpoints. Despite disappointment, the company remains committed to its brain disease treatment mission, with ongoing studies and a strong financial position.
Neumora Therapeutics Reports Disappointing Results from Phase 3 Study of Navacaprant in MDD
Navacaprant, a KOR antagonist for MDD, failed to meet primary and secondary endpoints in the phase 3 KOASTAL-1 trial, showing no significant improvement in MADRS or SHAPS scores. However, women showed greater improvement. No serious adverse events were reported. Further studies are planned.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Neumora's Phase 3 KOASTAL-1 Study of navacaprant for MDD did not meet primary efficacy endpoints but showed potential in female participants. Navacaprant was well-tolerated, with ongoing studies planned for further analysis.
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora Therapeutics' stock dropped after Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder failed to show significant improvement in primary and secondary endpoints. The company, with a $342 million cash balance, plans further updates and continues ongoing Phase 3 studies.
© Copyright 2025. All Rights Reserved by MedPath